Cargando…

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients

OBJECTIVES: The recently proposed standardized reporting and data system for somatostatin receptor (SSTR)–targeted PET/CT SSTR-RADS 1.0 showed promising first results in the assessment of diagnosis and treatment planning with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET...

Descripción completa

Detalles Bibliográficos
Autores principales: Grawe, Freba, Ebner, Ricarda, Geyer, Thomas, Beyer, Leonie, Winkelmann, Michael, Sheikh, Gabriel T., Eschbach, Ralf, Schmid-Tannwald, Christine, Cyran, Clemens C., Ricke, Jens, Bartenstein, Peter, Heimer, Maurice M., Faggioni, Lorenzo, Spitzweg, Christine, Fabritius, Matthias P., Auernhammer, Christoph J., Ruebenthaler, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121493/
https://www.ncbi.nlm.nih.gov/pubmed/36964768
http://dx.doi.org/10.1007/s00330-023-09518-y
_version_ 1785029381460066304
author Grawe, Freba
Ebner, Ricarda
Geyer, Thomas
Beyer, Leonie
Winkelmann, Michael
Sheikh, Gabriel T.
Eschbach, Ralf
Schmid-Tannwald, Christine
Cyran, Clemens C.
Ricke, Jens
Bartenstein, Peter
Heimer, Maurice M.
Faggioni, Lorenzo
Spitzweg, Christine
Fabritius, Matthias P.
Auernhammer, Christoph J.
Ruebenthaler, Johannes
author_facet Grawe, Freba
Ebner, Ricarda
Geyer, Thomas
Beyer, Leonie
Winkelmann, Michael
Sheikh, Gabriel T.
Eschbach, Ralf
Schmid-Tannwald, Christine
Cyran, Clemens C.
Ricke, Jens
Bartenstein, Peter
Heimer, Maurice M.
Faggioni, Lorenzo
Spitzweg, Christine
Fabritius, Matthias P.
Auernhammer, Christoph J.
Ruebenthaler, Johannes
author_sort Grawe, Freba
collection PubMed
description OBJECTIVES: The recently proposed standardized reporting and data system for somatostatin receptor (SSTR)–targeted PET/CT SSTR-RADS 1.0 showed promising first results in the assessment of diagnosis and treatment planning with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). This study aimed to determine the intra- and interreader agreement of SSTR-RADS 1.0. METHODS: SSTR-PET/CT scans of 100 patients were independently evaluated by 4 readers with different levels of expertise according to the SSTR-RADS 1.0 criteria at 2 time points within 6 weeks. For each scan, a maximum of five target lesions were freely chosen by each reader (not more than three lesions per organ) and stratified according to the SSTR-RADS 1.0 criteria. Overall scan score and binary decision on PRRT were assessed. Intra- and interreader agreement was determined using the intraclass correlation coefficient (ICC). RESULTS: Interreader agreement using SSTR-RADS 1.0 for identical target lesions (ICC ≥ 0.91) and overall scan score (ICC ≥ 0.93) was excellent. The decision to state “functional imaging fulfills requirements for PRRT and qualifies patient as potential candidate for PRRT” also demonstrated excellent agreement among all readers (ICC ≥ 0.86). Intrareader agreement was excellent even among different experience levels when comparing target lesion–based scores (ICC ≥ 0.98), overall scan score (ICC ≥ 0.93), and decision for PRRT (ICC ≥ 0.88). CONCLUSION: SSTR-RADS 1.0 represents a highly reproducible and accurate system for stratifying SSTR-targeted PET/CT scans with high intra- and interreader agreement. The system is a promising approach to standardize the diagnosis and treatment planning in NET patients. KEY POINTS: • SSTR-RADS 1.0 offers high reproducibility and accuracy. • SSTR-RADS 1.0 is a promising method to standardize diagnosis and treatment planning for patients with NET. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-023-09518-y.
format Online
Article
Text
id pubmed-10121493
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101214932023-04-23 Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients Grawe, Freba Ebner, Ricarda Geyer, Thomas Beyer, Leonie Winkelmann, Michael Sheikh, Gabriel T. Eschbach, Ralf Schmid-Tannwald, Christine Cyran, Clemens C. Ricke, Jens Bartenstein, Peter Heimer, Maurice M. Faggioni, Lorenzo Spitzweg, Christine Fabritius, Matthias P. Auernhammer, Christoph J. Ruebenthaler, Johannes Eur Radiol Molecular Imaging OBJECTIVES: The recently proposed standardized reporting and data system for somatostatin receptor (SSTR)–targeted PET/CT SSTR-RADS 1.0 showed promising first results in the assessment of diagnosis and treatment planning with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). This study aimed to determine the intra- and interreader agreement of SSTR-RADS 1.0. METHODS: SSTR-PET/CT scans of 100 patients were independently evaluated by 4 readers with different levels of expertise according to the SSTR-RADS 1.0 criteria at 2 time points within 6 weeks. For each scan, a maximum of five target lesions were freely chosen by each reader (not more than three lesions per organ) and stratified according to the SSTR-RADS 1.0 criteria. Overall scan score and binary decision on PRRT were assessed. Intra- and interreader agreement was determined using the intraclass correlation coefficient (ICC). RESULTS: Interreader agreement using SSTR-RADS 1.0 for identical target lesions (ICC ≥ 0.91) and overall scan score (ICC ≥ 0.93) was excellent. The decision to state “functional imaging fulfills requirements for PRRT and qualifies patient as potential candidate for PRRT” also demonstrated excellent agreement among all readers (ICC ≥ 0.86). Intrareader agreement was excellent even among different experience levels when comparing target lesion–based scores (ICC ≥ 0.98), overall scan score (ICC ≥ 0.93), and decision for PRRT (ICC ≥ 0.88). CONCLUSION: SSTR-RADS 1.0 represents a highly reproducible and accurate system for stratifying SSTR-targeted PET/CT scans with high intra- and interreader agreement. The system is a promising approach to standardize the diagnosis and treatment planning in NET patients. KEY POINTS: • SSTR-RADS 1.0 offers high reproducibility and accuracy. • SSTR-RADS 1.0 is a promising method to standardize diagnosis and treatment planning for patients with NET. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-023-09518-y. Springer Berlin Heidelberg 2023-03-25 2023 /pmc/articles/PMC10121493/ /pubmed/36964768 http://dx.doi.org/10.1007/s00330-023-09518-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Molecular Imaging
Grawe, Freba
Ebner, Ricarda
Geyer, Thomas
Beyer, Leonie
Winkelmann, Michael
Sheikh, Gabriel T.
Eschbach, Ralf
Schmid-Tannwald, Christine
Cyran, Clemens C.
Ricke, Jens
Bartenstein, Peter
Heimer, Maurice M.
Faggioni, Lorenzo
Spitzweg, Christine
Fabritius, Matthias P.
Auernhammer, Christoph J.
Ruebenthaler, Johannes
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
title Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
title_full Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
title_fullStr Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
title_full_unstemmed Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
title_short Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
title_sort validation of the sstr-rads 1.0 for the structured interpretation of sstr-pet/ct and treatment planning in neuroendocrine tumor (net) patients
topic Molecular Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121493/
https://www.ncbi.nlm.nih.gov/pubmed/36964768
http://dx.doi.org/10.1007/s00330-023-09518-y
work_keys_str_mv AT grawefreba validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT ebnerricarda validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT geyerthomas validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT beyerleonie validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT winkelmannmichael validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT sheikhgabrielt validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT eschbachralf validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT schmidtannwaldchristine validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT cyranclemensc validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT rickejens validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT bartensteinpeter validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT heimermauricem validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT faggionilorenzo validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT spitzwegchristine validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT fabritiusmatthiasp validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT auernhammerchristophj validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients
AT ruebenthalerjohannes validationofthesstrrads10forthestructuredinterpretationofsstrpetctandtreatmentplanninginneuroendocrinetumornetpatients